PURPOSE OF REVIEW: Deep brain stimulation (DBS) is now widely used in the treatment of Parkinson's disease, tremor, and dystonia. This review examines recent developments in the application of DBS to the management of movement disorders. RECENT FINDINGS: In Parkinson's disease, recent work has demonstrated that early DBS may have a significant benefit on quality of life and motor symptoms while permitting a decrease in levodopa equivalent dosage. Thalamic DBS continues to be a well established target for the treatment of tremor, although recent work suggests that alternative targets such as the posterior subthalamic area may be similarly efficacious. The treatment of primary dystonia with DBS has been established in multiple recent trials, demonstrating prolonged symptomatic benefit. SUMMARY: DBS is now an established symptomatic treatment modality for Parkinson's disease and other movement disorders. Future work will undoubtedly involve establishing new indications and targets in the treatment of movement disorders with further refinements to existing technology. Ultimately, these methods combined with biologically based therapies may catalyze a shift from symptomatic treatment to actually modifying the natural history of neurodegenerative diseases such as Parkinson's disease.
PURPOSE OF REVIEW: Deep brain stimulation (DBS) is now widely used in the treatment of Parkinson's disease, tremor, and dystonia. This review examines recent developments in the application of DBS to the management of movement disorders. RECENT FINDINGS: In Parkinson's disease, recent work has demonstrated that early DBS may have a significant benefit on quality of life and motor symptoms while permitting a decrease in levodopa equivalent dosage. Thalamic DBS continues to be a well established target for the treatment of tremor, although recent work suggests that alternative targets such as the posterior subthalamic area may be similarly efficacious. The treatment of primary dystonia with DBS has been established in multiple recent trials, demonstrating prolonged symptomatic benefit. SUMMARY: DBS is now an established symptomatic treatment modality for Parkinson's disease and other movement disorders. Future work will undoubtedly involve establishing new indications and targets in the treatment of movement disorders with further refinements to existing technology. Ultimately, these methods combined with biologically based therapies may catalyze a shift from symptomatic treatment to actually modifying the natural history of neurodegenerative diseases such as Parkinson's disease.
Authors: Elise Gondard; Lucy Teves; Lihua Wang; Chris McKinnon; Clement Hamani; Suneil K Kalia; Peter L Carlen; Michael Tymianski; Andres M Lozano Journal: J Neurosci Date: 2019-01-29 Impact factor: 6.167
Authors: Hannes O Tiedt; Felicitas Ehlen; Lea K Krugel; Andreas Horn; Andrea A Kühn; Fabian Klostermann Journal: Hum Brain Mapp Date: 2016-09-20 Impact factor: 5.038
Authors: Ali Falaki; Hang Jin Jo; Mechelle M Lewis; Barbara O'Connell; Sol De Jesus; James McInerney; Xuemei Huang; Mark L Latash Journal: Clin Neurophysiol Date: 2018-03-09 Impact factor: 3.708